Cited by 174Lymphatic System and DiseasesParasitic Diseases Research and TreatmentInflammatory mediators and NSAID effects

Leukotriene B 4 antagonism ameliorates experimental lymphedema

Tian, Wen, Rockson, Stanley G., Jiang, Xinguo, Kim, Jeanna, Begaye, Adrian, Shuffle, Eric M., Tu, Allen B., Cribb, Matthew +9 more·2017·Science Translational Medicine

Abstract

Acquired lymphedema is a cancer sequela and a global health problem currently lacking pharmacologic therapy. We have previously demonstrated that ketoprofen, an anti-inflammatory agent with dual 5-lipoxygenase and cyclooxygenase inhibitory properties, effectively reverses histopathology in experimental lymphedema. We show that the therapeutic benefit of ketoprofen is specifically attributable to its inhibition of the 5-lipoxygenase metabolite leukotriene B 4 (LTB 4 ). LTB 4 antagonism reversed edema, improved lymphatic function, and restored lymphatic architecture in the murine tail model of lymphedema. In vitro, LTB 4 was functionally bimodal: Lower LTB 4 concentrations promoted human lymphatic endothelial cell sprouting and growth, but higher concentrations inhibited lymphangiogenesis and induced apoptosis. During lymphedema progression, lymphatic fluid LTB 4 concentrations rose from initial prolymphangiogenic concentrations into an antilymphangiogenic range. LTB 4 biosynthesis was similarly elevated in lymphedema patients. Low concentrations of LTB 4 stimulated, whereas high concentrations of LTB 4 inhibited, vascular endothelial growth factor receptor 3 and Notch pathways in cultured human lymphatic endothelial cells. Lymphatic-specific Notch1 -/- mice were refractory to the beneficial effects of LTB 4 antagonism, suggesting that LTB 4 suppression of Notch signaling is an important mechanism in disease maintenance. In summary, we found that LTB 4 was harmful to lymphatic…

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aal3920

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ketoprofen and the LTB4 inhibitor bestatin showed promise in their respective mouse studies, but neither clinical trial produced limb volume reduction in lymphedema patients.

    “The nonsteroidal anti-inflammatory drug ketoprofen (148) and the leukotriene B4 (LTB4) inhibitor bestatin (44) showed promise in their respective mouse studies, but neither clinical trial produced limb volume reduction in lymphedema patients (trial identifiers NCT02257970, NCT02700529).”

    From Transport and Immune Functions of the Lymphatic System. (2025) · cites this paper as [44]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tian, W., Rockson, S. G., Jiang, X., Kim, J., Begaye, A., Shuffle, E. M., Tu, A. B., Cribb, M., Nepiyushchikh, Z., Feroze, A. H., Zamanian, R. T., Dhillon, G. S., Voelkel, N. F., Peters-Golden, M., Kitajewski, J., Dixon, J. B., & Nicolls, M. R.
Affiliations
  • VA Palo Alto Health Care System (US)
  • Stanford Medicine (US)
  • Georgia Institute of Technology (US)
  • Virginia Commonwealth University (US)
  • University of Michigan (US)
  • University of Illinois Chicago (US)
Corresponding author
  • Tian, Wen
  • Rockson, Stanley G.
  • Jiang, Xinguo
  • Kim, Jeanna
  • Nicolls, Mark R.
Venue
Science Translational Medicine
Published
2017-05-10
Volume
9
Issue
389
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2613046528
Cited by
173
References
65
Citations by year
2026: 17 · 2025: 8 · 2024: 16 · 2023: 17 · 2022: 22 · 2021: 24 · 2020: 22 · 2019: 24 · 2018: 17 · 2017: 6
FWCI
8.44
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (award295625)
Topics
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
  • Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
Keywords
leukotriene B4, leukotriene receptor antagonism, lymphedema, pathogenesis, therapeutic target
MeSH terms
Animals, Anti-Inflammatory Agents, Humans, Ketoprofen, Leukotriene B4, Lymphedema, Signal Transduction, Endothelial Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review